1stOncology™: Cancer Intelligence Service – Page 341 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Chugai Announces 2026 1st Quarter Results

On April 24, 2026 Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) reported its financial results for the first quarter of fiscal year 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Core revenue of ¥321.7 billion (+11.5%), core operating profit of ¥163.3 billion (+17.1%), and core net income of ¥118.6 billion (+19.6%) were achieved with strong sales performance of domestic and overseas products, resulting in increased revenue and profit (all changes year-on-year)
New product launches and additional indications included the launch of Elevidys as Japan’s first regenerative medical product for Duchenne muscular dystrophy (DMD), and the approval of Lunsumio and Polivy combination therapy for additional indication of relapsed or refractory large B‑cell lymphoma
R&D activities progressed steadily across both early and late-stage development, including Chugai-originated projects, with progress on track to achieving the highest number of application plans ever
NXT007 suggested favorable tolerability in Part C of the Phase I/II NXTAGE study for Hemophilia A following direct switching from Hemlibra without washout period
Enspryng presented Phase III results in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) at the 2026 American Academy of Neurology Annual Meeting, and is preparing for regulatory application within the year
Regarding products out-licensed to third parties, FoundayoTM(orforglipron), an oral GLP‑1 receptor agonist out‑licensed to Eli Lilly, has obtained U.S. approval as a treatment for obesity and is currently under regulatory review in more than 40 countries, including Japan and the European Union
Refer to the information below for details on the financial results:

Quarterly Reports / Finance Reports
View Source

Presentation Materials
In addition to Chugai’s business and financial performance, these materials provide updates on our research and development pipeline. Videos and scripts (including Q&A) will be made available at a later date.
View Source

[2026 First Quarter Results]

Core results (Billion JPY)
2026 2025 % change
Revenue

321.7

288.5 +11.5%
Domestic sales 111.4 103.0 +8.2%
Overseas sales 180.1 156.7 +14.9%
Other revenue 30.2 28.7 +5.2%
Operating profit 163.3
139.5

+17.1%
Net income 118.6 99.2 +19.6%

(Press release, Chugai, APR 24, 2026, View Source [SID1234664753])

Amphista Therapeutics announces presentation of new preclinical data from its SMARCA2 and TEAD Targeted Glue™ degrader programs at AACR 2026, and publication of the first data on its TEAD program

On April 24, 2026 Amphista Therapeutics ("the Company" or "Amphista"), a leader in the discovery and development of non-cereblon/non-VHL Targeted Glue degraders, reported the presentation of new pre-clinical data on its orally bioavailable SMARCA2 and TEAD Targeted Glue programs at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting in San Diego, US, and publication in bioRxiv of the optimization of early TEAD Targeted Glues.

Selective SMARCA2 Targeted Glue degraders:

Robust SMARCA2 selectivity over SMARCA4 maintained over time
Deep degradation of SMARCA2 following oral delivery
New data from the DCAF16-dependent SMARCA2 program demonstrated deep in vivo degradation of SMARCA2 following oral dosing. In vivo SMARCA2 degradation translated into suppression of downstream biomarkers, including KRT80 and PLAU, reinforcing the therapeutic relevance of the approach. The program leverages insights gained from multiple high-resolution cryo-electron microscopy structures of the ternary complex, enabling improvements in the speed and depth of SMARCA2, as well as high degradation selectivity over the closely related SMARCA4 paralog. Together, these data support a best-in-class potential for Amphista’s SMARCA2 Targeted Glue degraders.

TEAD Targeted Glue degraders:

Oral in vivo tumor regression following intermittent dosing
bioRxiv publication on the rational and systematic optimization of early TEAD Targeted Glues
New data from the FBXO22-dependent TEAD program demonstrated anti-proliferative activity in mesothelioma cell lines, with synergistic efficacy observed in combination with osimertinib in vitro in an EGFR-mutant NSCLC model. Further data showcased how a degradation-based modality, combined with the long half-life of TEAD, drives extended pharmacodynamic effects, enabling an efficacious once-every-three-day dosing schedule and tumor regression in vivo in a mesothelioma xenograft model. The bioRxiv publication describes the rational and systematic optimization of early FBXO22 Cys326-mediated TEAD Targeted Glues, achieving enhanced degradation potency and kinetics compared to previously reported FBXO22-targeting approaches. These findings establish important design principles for this emerging degrader class and validate FBXO22-TEAD degradation as a therapeutically relevant approach for Hippo pathway-driven cancers, with promise in mesothelioma and combination strategies for EGFR-mutant NSCLC.

Dr. Louise Modis, Chief Executive Officer at Amphista Therapeutics, commented: "The positive preclinical data on two of our programs, SMARCA2 and TEAD, reflect the strength of our unique approach and proprietary technology, and the great progress we are making as we advance towards the clinic. We are actively seeking partners to collaborate on our SMARCA2 and TEAD programs as they progress towards candidate selection in the second half of 2026."

Today’s announcement builds on the progress Amphista has made since it disclosed its SMARCA2 and TEAD programs in September 2025 and follows the recent presentation of AMX-883, an orally bioavailable, highly potent and selective degrader of BRD9, at AACR (Free AACR Whitepaper) 2026.
BioRxiv publication details:

Title: Identification and SAR optimization of FBXO22-mediated TEAD Targeted Glue degraders

DOI: View Source

Poster presentations details:

Title: Rational development of novel DCAF16-mediated SMARCA2 selective Targeted Glues for the treatment of SMARCA4 deficient tumors

Session: Proximity-Induced Drug Discovery 1

Presenter: James Lynch, Senior Director Bioscience, Amphista Therapeutics

Title: Rational development of novel FBXO22-mediated TEAD Targeted Glues for Mesothelioma and NSCLC Treatment

Session: Targeted Protein Degradation and Induced Proximity

Presenter: Marta Carrara, Associate Director Bioscience, Amphista Therapeutics

(Press release, Amphista Therapeutics, APR 24, 2026, View Source [SID1234664752])

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

On April 24, 2026 Aligos Therapeutics, Inc. (Nasdaq: ALGS, "Aligos", "Company"), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, reported that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase an aggregate of 10,700 shares of the Company’s stock (the "Inducement Grant") to newly hired employees on April 22, 2026 (the "Grant Date"), in connection with the commencement of employment.

The Inducement Grants were granted pursuant to Aligos’ 2024 Inducement Plan (the "Plan") as an inducement material to these individuals entering employment in accordance with Nasdaq Listing Rule 5635(c)(4). The Plan is used exclusively for the grant of equity awards to individuals who were not previously employed by Aligos.

The Inducement Grants have an exercise price per share equal to the closing price of Aligos’ common stock on the Grant Date. The shares subject to the Inducement Grant will vest over a four-year period, with 25% vesting on the first anniversary of the Grant Date and the remainder vesting in equal monthly installments, subject to the continued employment through the applicable vesting dates.

(Press release, Aligos Therapeutics, APR 24, 2026, View Source [SID1234664750])

Novartis withdraws EMA application for adding new indication for Pluvicto®

On April 24, 2026 Novartis reported it has withdrawn a European Medical Agency type II variation application for Pluvicto to treat adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC)1 pre-chemotherapy, following CHMP feedback. The CHMP indicated that they would not support the application based on the control arm used in the PSMAfore study. The withdrawal is not related to the quality, efficacy or safety of Pluvicto and does not impact ongoing clinical trials, approved indications or pending regulatory submissions inside or outside the EU.

Importantly, the PSMAfore study that supported the application, was the basis for successful approval of Pluvicto in pre-chemotherapy mCRPC patients in the United States, Japan, and China. The value of Pluvicto in this population is also reflected in evidence-based recommendations from leading professional guidelines, including ESMO (Free ESMO Whitepaper), EAU, ASCO (Free ASCO Whitepaper) and NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)2.

We are disappointed by this outcome and remain committed to advancing treatment options for people with prostate cancer.

(Press release, Novartis, APR 24, 2026, View Source [SID1234664748])

Roche reports strong sales growth of +6% at constant exchange rates in the first quarter of 2026; -5% in CHF due to the significant appreciation of the Swiss franc

On April 23, 2026 Hoffmann-La Roche reported strong sales growth of +6% at constant exchange rates in the first quarter of 2026.

(Press release, Hoffmann-La Roche, APR 23, 2026, View Source [SID1234669136])